Erasca, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 14.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.02B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Details
| Name | Erasca, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 103 |
| Founded | 2018 |
| Ipo Date | 2021-07-16 |
| Ceo | Jonathan Lim |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US29479A1088 |
| Cusip | 29479A108 |
| Cik | 1761918 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. David M. Chacko M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research and Development, Scientific Advisory Board Member and Director |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Alison Tjosvold Milhous | Senior Vice President of Accounting |
| Dr. Robert Shoemaker Ph.D. | Chief Scientific Officer |
| Ebun S. Garner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |
Contact
| Address | 3115 Merryfield Row, Suite 300, San Diego, California 92121, United States |
| Phone | 858 465 6511 |
| Website | https://www.erasca.com |